Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Decade in review—clinical rheumatology

10 years of therapeutic advances in the rheumatic diseases

In the past 10 years, the rheumatology community has seen an explosion in the number of new therapies licensed for use across the rheumatic diseases, many with outstanding clinical success. Here, the drugs and strategies that constitute landmarks in the management of rheumatic diseases are highlighted.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Norman, P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin. Investig. Drugs 23, 1067–1077 (2014).

    Article  CAS  Google Scholar 

  2. Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020–1026 (2014).

    Article  CAS  Google Scholar 

  3. McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780–789 (2013).

    Article  CAS  Google Scholar 

  4. Stohl, W. & Hilbert, D. M. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat. Biotechnol. 30, 69–77 (2012).

    Article  CAS  Google Scholar 

  5. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).

    Article  CAS  Google Scholar 

  6. Matucci-Cerinic, M. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 70, 32–38 (2011).

    Article  CAS  Google Scholar 

  7. De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385–2395 (2012).

    Article  CAS  Google Scholar 

  8. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).

    Article  CAS  Google Scholar 

  9. Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. Two randomized controlled trials. JAMA 306, 711–720 (2011).

    Article  CAS  Google Scholar 

  10. Baeten, D. et al. Anti-interleukin-17A monoclonal antibody secukinumabin treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382, 1705–1713 (2013).

    Article  CAS  Google Scholar 

Download references


Work in the author's laboratory is supported by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre, based at Newcastle Hospitals NHS Foundation Trust and Newcastle University, UK. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. The author is grateful to T. Aspray and P. Conaghan for their insights whilst preparing thismanuscript.

Author information

Authors and Affiliations


Corresponding author

Correspondence to John D. Isaacs.

Ethics declarations

Competing interests

The author has been a member of advisory boards for Celltrion, Hospira, Janssen, Novartis, Pfizer and Roche.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Isaacs, J. 10 years of therapeutic advances in the rheumatic diseases. Nat Rev Rheumatol 11, 628–630 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research